Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.

Abstract: A method of diagnosing and treating proliferative disorders in connection with the use of a Smac mimetic.

Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.

Abstract: The invention relates to the prevention and/or treatment of skeletal related disorders using heteroaryl compounds.

Abstract: A combination therapy comprising administration of a Smac mimetic and GM-CSF.

Abstract: The invention relates to the prevention and/or treatment of skeletal related disorders using heteroaryl compounds.

Abstract: The present invention relates generally to a regulatory molecule and to genetic sequences encoding same. More particularly, the present invention provides a molecule involved in, associated with or which otherwise facilitates myogenesis. In a particularly preferred embodiment, the regulatory molecule is a transcription factor involved in the expression of genes resulting in the determination of skeletal muscle (a sequence encoding the regulatory molecule is disclosed within the specification as Seq. Id. No: 2). The identification of the regulatory molecule of the present invention permits the development of agents capable of modulating myogenesis including therapeutic agents capable of ameliorating aberrations in pyogenesis such as but not limited to myogenic cancers.

Abstract: The present invention relates generally to a method for controlling fertility and/or modulating the maintenance of pregnancy in animals. The present invention further provides an animal model useful for screening for therapeutic agents to treat infertility, to prevent or reduce spontaneous abortion and/or as contraceptive agents in animals.

Abstract: The present invention relates to a method for modulating fertility in an animal by administering an effective amount of IL-11 or derivatives or homologues thereof or an effective amount of an agonist or antagonist of the interaction between IL-11 and IL-11R&agr;.

Abstract: The present invention relates generally to a method for the treatment or prophylaxis of animals including humans suffering from or predisposed to breast cancer or other related cancers which comprises the use of cytokines and/or functionally active derivatives, hybrids and/or analogs thereof and to pharmaceutical compositions comprising same as therapeutic agents. In particular, but not exclusively, the present invention is directed to the use of cytokines which are ligands of members of the haemopoietin receptor super family or their derivatives, hybrids or analogues as therapeutic agents. The present application also contemplates breast cancer therapies and methods of suppressing growth of normal breast cells or breast cancer cells by the use of one or more cytokines optionally in combination with other therapeutic agents as well as the use of agonists or antagonists of cytokine activity. Particularly preferred are oncostatin M (OSM) and leukemia inhibitory factor (LIF).

Abstract: We have identified a new human gene, SCL. We discovered this gene because of its involvement in a chromosomal translocation associated with the occurrence of a stem cell leukemia manifesting myeloid and lymphoid differentiation capabilities. Here we report the sequence of a cDNA for the normal SCL transcript, as well as for an aberrant fusion transcript produced in the leukemic cells. Although different at their 3' untranslated regions, both cDNAs predict a protein with primary amino acid sequence homology to the previously described amphipathic helix-loop-helix DNA binding and dimerization motif of the Lyl-1, myc, MyoD, Ig enhancer binding, daughterless, and achaete-scute families of genes. For these cDNAs, two forms of the SCL protein (greater than 20 and 30 kD) are predicted, both of which retain this putative DNA binding domain. The pattern of expression of SCL mRNA is primarily predominant in early hematopoietic tissues.

Abstract: We have identified a new human gene, SCL. We discovered this gene because of its involvement in a chromosomal translocation associated with the occurrence of a stem cell leukemia manifesting myeloid and lymphoid differentiation capabilities. Here we report the sequence of a cDNA for the normal SCL transcript, as well as for an aberrant fusion transcript produced in the leukemic cells. Although different at their 3' untranslated regions, both cDNAs predict a protein with primary amino acid sequence homology to the previously described amphipathic helix-loop-helix DNA binding and dimerization motif of the Lyl-1, myc, MyoD, Ig enhancer binding, daughterless, and achaete-scute families of genes. For these cDNAs, two forms of the SCL protein (greater than 20 and 30 kD) are predicted, both of which retain this putative DNA binding domain. The pattern of expression of SCL mRNA is primarily predominant in early hematopoietic tissues.